News | February 03, 2009

NCCN Updates Breast Cancer, Breast Cancer Risk Reduction Guidelines

February 3, 2009 - The National Comprehensive Cancer Network (NCCN) said it has made important updates to the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer and Breast Cancer Risk Reduction.

These changes reportedly reflect leading developments in the treatment of patients with breast cancer and represent the standard of clinical policy in oncology in both community and academic settings.

Notable diagnostic additions to the NCCN Guidelines include a recommendation for genetic counseling if the patient is high risk for hereditary breast cancer, as well as six new recommendations detailing when MRIs may be helpful in breast cancer evaluations.

Conversely, the updated NCCN Guidelines for Breast Cancer state that PET/CT scanning is not recommended for evaluation of newly diagnosed patients with early stage disease except in those clinical situations where other staging studies are equivocal or suspicious, and even in these situations that biopsy is recommended. The NCCN Guideline Panel Members for Breast Cancer note that although there is limited evidence demonstrating the utility of PET/CT scan in the staging of patients, they consider biopsy to be more likely to provide useful staging information.

The updated NCCN Guidelines continue to recognize bisphosphonates as the preferred intervention to treat osteoporosis in women with breast cancer, while the use of estrogen, progesterone, or selective estrogen receptor modulators is discouraged.

Significant additions were also made to the portion of the NCCN Guidelines providing recommendations for patients undergoing breast reconstruction following surgery. It is now recommended that women receive an evaluation detailing the likely cosmetic outcome of a lumpectomy prior to the actual surgery. Furthermore, women who are not satisfied with the cosmetic outcome following completion of breast cancer treatment should be offered a plastic surgery consultation.

Notable additions to the NCCN Guidelines for Breast Cancer Risk Reduction include updates to two risk-reduction agents, tamoxifen (Soltamox, AstraZeneca) and raloxifine (Evista, Eli Lilly and Company). Tamoxifen is recommended for premenopausal women with a history of atypical hyperplasia to reduce breast cancer risk. For postmenopausal women, raloxifene is listed as equivalent to tamoxifen in reducing the risk of developing invasive breast cancer; however, it did not provide the same level of risk reduction for developing non-invasive breast cancer.

Breast cancer remains the second leading cause of cancer death after lung cancer in women in the United States. It is estimated that more than 180,000 new cases of breast cancer will be diagnosed in women in 2009.

NCCN Clinical Practice Guidelines in Oncology(TM) are developed and updated through an evidence-based process with explicit review of the scientific evidence by multidisciplinary panels of expert physicians from NCCN Member Institutions.

For more information: www.nccn.org

Related Content

PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
Videos | Breast Density | April 26, 2018
ITN Editorial Director Melinda Taschetta-Millane speaks to DenseBreast-info Executive Director JoAnn Pushkin
ACR/SBI Breast Cancer Screening Guidelines Reclassify African-American Women as High-Risk
News | Breast Imaging | April 06, 2018
New American College of Radiology (ACR) and Society of Breast Imaging (SBI) breast cancer screening guidelines are the...
ACR Recommends More Aggressive Breast Cancer Screening for Higher-Than-Average-Risk Women
News | Breast Imaging | March 29, 2018
The American College of Radiology (ACR) released new breast cancer screening guidelines recommending all women,...
In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows).

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Image courtesy of A Piccardo et al., Galliera Hospital, Genoa, Italy.

News | Prostate Cancer | March 07, 2018
An Italian study featured in the March i
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
Overlay Init